Barclays PLC Acquires 175,177 Shares of Xencor, Inc. (NASDAQ:XNCR)

Barclays PLC increased its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 112.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 330,745 shares of the biopharmaceutical company's stock after acquiring an additional 175,177 shares during the quarter. Barclays PLC owned about 0.47% of Xencor worth $7,600,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of XNCR. Sterling Capital Management LLC grew its position in Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares during the last quarter. GAMMA Investing LLC grew its position in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV grew its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 813 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares during the period. Finally, Summit Investment Advisors Inc. raised its holdings in Xencor by 22.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 1,282 shares in the last quarter.

Xencor Price Performance

Shares of NASDAQ:XNCR traded down $0.33 on Friday, hitting $10.51. The stock had a trading volume of 463,505 shares, compared to its average volume of 628,717. The firm's 50 day moving average price is $11.77 and its 200-day moving average price is $18.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a market capitalization of $740.56 million, a price-to-earnings ratio of -3.28 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. William Blair initiated coverage on Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Wells Fargo & Company lowered their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $33.86.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.